Biolife Solutions, Inc. · NASDAQ:BLFS
Biolife Solutions — Investor Presentation (February 2018)
25 slides from Biolife Solutions's investor presentation, Feb 12, 2018
Slide 1: Investor Presentation: Biopreservation Tools for Cells, Tissues and Organs
© 2018 BIOLIFE SOLUTIONS, INC. NASDAQ: BLFS Investor Presentation Biopreservation Tools for Cells, Tissues and Organs
Slide 2: Safe Harbor Statement
© 2018 BIOLIFE SOLUTIONS, INC. Safe Harbor Statement Except for historical information contained herein, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . These forward - looking statements include, but are not limite
Slide 3: Mission
© 2018 BIOLIFE SOLUTIONS, INC. Mission Become the leading provider of biopreservation tools for cells, tissues, and organs By supplying best - in - class tools for maintaining the health and function of biologic source material and finished products during manufacturing, storage and distribution WHA
Slide 4: Best in Class Biopreservation Media
© 2018 BIOLIFE SOLUTIONS, INC. Best in Class Biopreservation Media CryoStor® Freeze Media x Used in more than 275 customer clinical applications x Embedded in dozens of leading CAR T - cell clinical trials x Engineered to maximize efficacy of cell - based therapies HypoThermosol® Storage & Shipping
Slide 5: Investment Thesis
© 2018 BIOLIFE SOLUTIONS, INC. Investment Thesis • Enabling cellular therapies; potential cures for cancer and other leading causes of death; by supplying embedded preservation technologies to keep cell - based therapies viable until patient administration • Proprietary IP and sticky customer relati
Slide 6: Strategic Revenue Markets and Channels
© 2018 BIOLIFE SOLUTIONS, INC. Strategic Revenue Markets and Channels BIOBANKING 11% OF 2017 Umbilical cord blood banks Adult stem cell banks Tissue banks Biorepositories Hair transplant physicians DRUG DISCOVERY Pharmaceutical companies Cell suppliers Toxicity testing labs Personalized medicine lab
Slide 7: Biopreservation Challenges
© 2018 BIOLIFE SOLUTIONS, INC. Biopreservation Challenges Survival – How Long Viability – How Many Function – How Well Ex Vivo Time Viability Ex Vivo Time Survival Ex Vivo Time Function Cold storage is used to preserve biologic integrity and function by lowering metabolism . CAR T and other cell the
Slide 8: Extending Biologic Shelf-Life
© 2018 BIOLIFE SOLUTIONS, INC. Cells Preserved in traditional “home brew” Human mesenchymal stem cells isolated from bone marrow; condition of cells after 5 days of cold storage, then returned to culture conditions and assayed 24 hours later Extending Biologic Shelf - Life Cells Preserved in HypoThe
Slide 9: Biopreservation Yield: COGS and Efficacy
© 2018 BIOLIFE SOLUTIONS, INC. Biopreservation Yield: COGS and Efficacy Cost Cost Yield Yield LESS Required to Achieve Desired Therapeutic Effect Source Material Manufactured Cell Products LESS Required MORE Doses = 9
Slide 10: CryoStor Freeze Media
© 2018 BIOLIFE SOLUTIONS, INC. Serum - free, protein - free, animal - origin free; highest - quality ingredients; US FDA Master File CryoStor® Freeze Media Improved cell viability and functional recovery compared to commercial and home - brew alternatives in numerous cell types Formulated to mitigat
Slide 11: HypoThermosol Storage Media
© 2018 BIOLIFE SOLUTIONS, INC. HypoThermosol® Storage Media Optimized for hypothermic (2 - 8 ° C) storage and shipping of cells and tissues Enables multiple days of cell and tissue storage for transport of source material and manufactured cell products throughout the world Serum - free, protein - fr
Slide 12: Cell Therapy Manufacturing Workflow and Customer Engagement
© 2018 BIOLIFE SOLUTIONS, INC. Source Material Preservation Media Cell Factory Final Manufactured Product evo® CRYO LN2 Preservation Media Cell Therapy Manufacturing Workflow Biopreservation Media and Cold Chain Tools for Source Material and Final Dose Patient Temperature Controlled Container evo® C
Slide 13: Regenerative Medicine Market
© 2018 BIOLIFE SOLUTIONS, INC. Regenerative Medicine Market August 2017 $12B Gilead Acquisition of Kite August 2017 Novartis Kymriah™ CAR - T Cell Therapy Approved October 2017 Kite Yescarta™ CAR - T Cell Therapy Approved 13 Jan 2018 $ 9 B Celgene Acquisition of Juno $22B Invested in 2015 - 2017
Slide 14: Broad, High Value Customer Base
© 2018 BIOLIFE SOLUTIONS, INC. Broad, High Value Customer Base DISTRIBUTORS CMO & CDMO CELL THERAPY MARKET 14
Slide 15: FDA – Customer Approval
© 2018 BIOLIFE SOLUTIONS, INC. FDA – Customer Approval • Kite Pharma (Gilead) YESCARTA™ CAR T Cell Therapy • US FDA approval in October 2017 for adult patients with relapsed or refractory large B - Cell lymphoma after two or more lines of systemic therapy • Our CryoStor ® freeze media is embedded in
Slide 16: Customer Approval
© 2018 BIOLIFE SOLUTIONS, INC. Customer Approval • Kolon Life Science – Invossa™ • Cell - mediated gene therapy for knee osteoarthritis shipped frozen • Each dose is frozen in our CryoStor® cell freeze media • Approved in Korea; estimated 5M patients • Worldwide patient population estimated at 150M
Slide 17: Financial Highlights
© 2018 BIOLIFE SOLUTIONS, INC. Financial Highlights 17
Slide 18: Executing for Growth
© 2018 BIOLIFE SOLUTIONS, INC. Executing for Growth 50% 52% 54% 56% 58% 60% 62% 64% 66% 68% 70% $0 $2,000,000 $4,000,000 $6,000,000 $8,000,000 $10,000,000 $12,000,000 $14,000,000 $16,000,000 $18,000,000 $20,000,000 2015 2016 2017E 2018E 35% CAGR with Significant Operating Leverage Revenue Gross Marg
Slide 19: Q3 2017 Financial Results
© 2018 BIOLIFE SOLUTIONS, INC. Q3 2017 Financial Results (In Thousands) Q3 2017 Q3 2016 CHANGE % CHANGE Revenue* $ 2,963 $ 2,135 $ 828 39% COGS 1,095 921 174 19% Gross Margin % 63% 57% 6pts N/A OPEX 1,900 2,352 (452) (19%) Operating Loss (32) (1,138) (1,106) N/A Adjusted EBITDA 298 (567) 865 N/A Cas
Slide 20: Annual and Quarterly Revenue Growth
© 2018 BIOLIFE SOLUTIONS, INC. $0 $2,000,000 $4,000,000 $6,000,000 $8,000,000 $10,000,000 $12,000,000 FY2016 FY2017 Annual Revenue Growth Preliminary Q4 and FY 2017 Revenue $2,000,000 $2,200,000 $2,400,000 $2,600,000 $2,800,000 $3,000,000 $3,200,000 $3,400,000 Q4 16 Q3 17 Q4 17 Quarterly Revenue Gro
Slide 21: 2018 Guidance
© 2018 BIOLIFE SOLUTIONS, INC. 2018 Guidance Metric 2018 2018 change from 2017 Revenue $13.6M - $14.7M Up to 35% growth Gross Margin 62% - 64% Up to 400 bps OPEX $9 - $9.5M 12% - 18% increase GAAP Operating Profit Full year positive First time in Company history Adjusted EBITDA Significant increase
Slide 22: Cap Table – 24.5mm Fully Diluted Shares
© 2018 BIOLIFE SOLUTIONS, INC. Cap Table – 24.5mm Fully Diluted Shares ▪ 5.6mm @ $4.75 ▪ 550K @ $1.75 ▪ 3.9mm held by the same two long term shareholders ▪ Management and employee incentives ▪ 1.6mm vested ▪ $1.79 wt. avg exercise price ▪ Increasing institutional holders ▪ 46% held by two long term
Slide 23: Experienced Executive Team
© 2018 BIOLIFE SOLUTIONS, INC. Experienced Executive Team Mike Rice – Chief Executive Officer BS Bus Admin; 10 years as BLFS CEO; chief visionary of BLFS market opportunities, branding, marketing strategies; 18 years medical device sales, sales management, marketing; patient monitoring, defibrillato
Slide 24: Investment Thesis
© 2018 BIOLIFE SOLUTIONS, INC. Investment Thesis • Enabling cellular therapies; potential cures for cancer and other leading causes of death; by supplying embedded preservation technologies to keep cell - based therapies viable until patient administration • Proprietary IP and sticky customer relati
Slide 25: Contact
© 2018 BIOLIFE SOLUTIONS, INC. NASDAQ: BLFS For additional questions or comments, please contact: Mike Rice | President and CEO mrice@BioLifeSolutions.com | (425) 686 - 6003 Roderick de Greef | CFO rdegreef@BioLifeSolutions.com | (425) 686 - 6002 www.biolifesolutions.com BioLife Solutions, Inc. 3303
Biolife Solutions — Investor Presentation (February 2018) on 6ix